TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 380963

Group type: EXPERIMENTAL
Intervention: Indomethacin (Amuno, Indocid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31369124

Group type: EXPERIMENTAL
Intervention: Continuous genetic scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2×2 approach
Number of subjects: 0
Study: 29484638

Group type: EXPERIMENTAL
Intervention: GDC-0853 (≤600 mg, single ascending dose; ≤250 mg twice daily; ≤500 mg once daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDC-0853
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDC-0853 (100 mg, once daily)
Number of subjects: 0
Study: 28827417

Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 900 mg rifampin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1,200 mg rifampin
Number of subjects: 150

Group type: COMPARATOR
Intervention: rifampin (600 mg, 900 mg, 1,200 mg)
Number of subjects: 150
Study: 23757100

Group type: EXPERIMENTAL
Intervention: Universal prevention measures in kindergarten setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective prevention measures in kindergarten setting
Number of subjects: 0
Study: 23904465

Group type: EXPERIMENTAL
Intervention: BPA exposure (20, 200 ng/ml or 20 µg/ml)
Number of subjects: 121
Study: 21961465

Group type: EXPERIMENTAL
Intervention: DPP Lifestyle program
Number of subjects: 228

Group type: COMPARATOR
Intervention: Attention control intervention (cognitive training)
Number of subjects: 228
Study: 20298323

Group type: EXPERIMENTAL
Intervention: ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd)
Number of subjects: 61

Group type: COMPARATOR
Intervention: ICS alone (500 mcg bd)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mild symptoms group
Number of subjects: 61
Study: 16176606

Group type: EXPERIMENTAL
Intervention: Soya foods (two daily servings including tofu, soya milk, soya nuts, and soya protein powder; equivalent to 50 mg isoflavones and 5-22 g soya protein per serving)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (maintained regular diet)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Soya foods
Number of subjects: 196
Study: 12548322

Group type: EXPERIMENTAL
Intervention: Outpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Inpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Number of subjects: 300
Study: 10778689

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 32
Study: 8903808

Group type: EXPERIMENTAL
Intervention: Protective lead shield
Number of subjects: 20

Group type: COMPARATOR
Intervention: No protective shield
Number of subjects: 20
Study: 1846331

Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous timolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg quinidine pretreatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isoproterenol infusions
Number of subjects: 6
Study: 7082538

Group type: EXPERIMENTAL
Intervention: Long-term oral cimetidine treatment
Number of subjects: 12
Study: 29890239

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27981688

Group type: EXPERIMENTAL
Intervention: CLARIFIG static
Number of subjects: 682

Group type: COMPARATOR
Intervention: MFP static
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: CLARIFIG animated
Number of subjects: 682

Group type: COMPARATOR
Intervention: MFP animated
Number of subjects: 682
Study: 26034240

Group type: EXPERIMENTAL
Intervention: Physician-targeted communication training
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Physician self-efficacy in communicating with parents
Number of subjects: 347
Study: 24797376

Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg IV thrice weekly for up to 2 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 22278344

Group type: EXPERIMENTAL
Intervention: 84 mg soy germ isoflavones
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 126 mg soy germ isoflavones
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0 mg soy germ isoflavones)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment groups (84 mg, 126 mg, and placebo)
Number of subjects: 90
Study: 19338655

Group type: COMPARATOR
Intervention: Patient safety program addressing pressure ulcers, falls, and urinary tract infections, implemented for fourteen months after a three-month baseline period and followed by a nine-month follow-up.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patient safety program
Number of subjects: 20
Study: 17602019

Group type: EXPERIMENTAL
Intervention: Family psychoeducation group program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 84
Study: 15293895

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg per day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no tibolone)
Number of subjects: 82
Study: 11251483

Group type: EXPERIMENTAL
Intervention: Nonsutured
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sutured
Number of subjects: 80
Study: 9307692

Group type: EXPERIMENTAL
Intervention: Morning light therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal controls (no intervention)
Number of subjects: 12
Study: 8316616

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC) for 3 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3577356

Group type: EXPERIMENTAL
Intervention: Trivalent split vaccine (15 micrograms haemagglutinin of A-H3N2, A-H1N1, and B strains)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Booster injection of the same vaccine dosage four weeks after the first immunization
Number of subjects: 101

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 101
Study: 30712326

Group type: EXPERIMENTAL
Intervention: Good psychiatric management treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Good psychiatric management treatment with the addition of the Motive‐Oriented Therapeutic Relationship
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 37
Study: 30541217

Group type: EXPERIMENTAL
Intervention: Berberine (0.4 g, 3 times a day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (only hypoglycemic agents)
Number of subjects: 114
Study: 27998236

Group type: EXPERIMENTAL
Intervention: Seribantumab plus paclitaxel
Number of subjects: 223

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Seribantumab plus paclitaxel (in patients with detectable HRG mRNA and low HER2)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Paclitaxel alone (in patients with detectable HRG mRNA and low HER2)
Number of subjects: 223
Study: 24742381

Group type: EXPERIMENTAL
Intervention: mHealth cognitive stimulation therapy (therapist-assisted) for 4 weeks, 2-3 days/week
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (treatment-as-usual with no neuropsychological intervention)
Number of subjects: 68
Study: 22212621

Group type: EXPERIMENTAL
Intervention: Attainment of KDOQI clinical performance targets
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Number of performance targets reached
Number of subjects: 715
Study: 20061884

Group type: EXPERIMENTAL
Intervention: Increased availability of healthy items to 50% and price reductions of at least 10% in vending machines at two bus garages.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with usual availability and prices in two bus garages.
Number of subjects: 33
Study: 18227331

Group type: EXPERIMENTAL
Intervention: Repetitive hand exercise for 5 min (exercise group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resting arms after ISB (nonexercise group)
Number of subjects: 40
Study: 16164466

Group type: EXPERIMENTAL
Intervention: Maximum bite force during submerged healing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maximum bite force during functional loading
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sequence of attachment types (ball, magnet, bar-clip)
Number of subjects: 18
Study: 12634966

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) in patients with angiographic no reflow (group 1)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) in patients without angiographic no reflow (group 2)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Angiographic no reflow
Number of subjects: 117
Study: 10815576

Group type: EXPERIMENTAL
Intervention: Oral health promotion programme
Number of subjects: 500

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 500
Study: 7557599

Group type: EXPERIMENTAL
Intervention: Preoperative adjuvant chemotherapy (VBP scheme)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Radical surgery without preoperative adjuvant chemotherapy (Control)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Preoperative adjuvant chemotherapy
Number of subjects: 230
Study: 2148321

Group type: EXPERIMENTAL
Intervention: Topical administration of glucosyltransferase (GTF) combined with aluminum phosphate (AP) daily for 5 days.
Number of subjects: 20
Study: 7387491

Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (2.5 to 20.0 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (after cessation of therapy)
Number of subjects: 8
Study: 31609716

Group type: EXPERIMENTAL
Intervention: Trunk‐based vibrotactile sensory augmentation (SA) during balance exercises
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (CG) - balance training without SA
Number of subjects: 8
Study: 29432350

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 180
Study: 26893187

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg p.o. once daily for 52 weeks
Number of subjects: 120
Study: 24527605

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 82
Study: 22613427

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA group)
Number of subjects: 24
Study: 20942274

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 17507264

Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 32

Group type: COMPARATOR
Intervention: Buccal envelope flap
Number of subjects: 32
Study: 16042664

Group type: EXPERIMENTAL
Intervention: Sotalol + Telithromycin (800 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sotalol + Placebo
Number of subjects: 24
Study: 12177257

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation (donors)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No preoperative autologous blood donation (nondonors)
Number of subjects: 96
Study: 9863281

Group type: EXPERIMENTAL
Intervention: Low-dose etretinate combined with eicosapentaenoic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose etretinate alone
Number of subjects: 40
Study: 8548058

Group type: EXPERIMENTAL
Intervention: Human galanin (hGAL) infusion (80 pmol.kg‐1.min‐1) for 60 minutes
Number of subjects: 9
Study: 1978443

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulins (0.4 g/kg body weight IVIG every other week for 26 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (albumin 0.03% every other week for 26 weeks)
Number of subjects: 30
Study: 103182

Group type: EXPERIMENTAL
Intervention: 2% aqueous solution of sodium cromoglycate
Number of subjects: 37
Study: 7263746

Group type: EXPERIMENTAL
Intervention: Internal fixation using Garden screws
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Thompson hemiarthroplasty through a posterior (Moore) approach
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Thompson hemiarthroplasty through an anterolateral (McKee) approach
Number of subjects: 218
Study: 30683457

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.5 mg/day)
Number of subjects: 28
Study: 29493714

Group type: EXPERIMENTAL
Intervention: Educational intervention on skin-protective behavior
Number of subjects: 756

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 756
Study: 27173818

Group type: EXPERIMENTAL
Intervention: Intervention group (letter sent to patients and general practitioners)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (care-as-usual)
Number of subjects: 248
Study: 25225745

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 22172725

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) measured at baseline
Number of subjects: 1889
Study: 20839670

Group type: EXPERIMENTAL
Intervention: Transepithelial treatment (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subepithelial treatment (group 2)
Number of subjects: 100
Study: 16730113

Group type: EXPERIMENTAL
Intervention: Amnioinfusion via a two-way catheter
Number of subjects: 86
Study: 15906755

Group type: EXPERIMENTAL
Intervention: LAC+CET (lansoprazole, amoxicillin, clarithromycin, and cetraxate)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: LEFT (LAC for 7 days in a horizontal body position on the left side)
Number of subjects: 55

Group type: COMPARATOR
Intervention: LAC (lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 55
Study: 12002492

Group type: EXPERIMENTAL
Intervention: LARS artificial ligament
Number of subjects: 53

Group type: COMPARATOR
Intervention: ipsilateral bone‐patellar‐tendon‐bone autograft
Number of subjects: 53
Study: 10445773

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine 0.75% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Number of subjects: 90
Study: 7790241

Group type: EXPERIMENTAL
Intervention: RT+ETA (radiotherapy plus etanidazole)
Number of subjects: 504

Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 504
Study: 2192405

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% (n = 24)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (n = 21)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% (n = 20)
Number of subjects: 65
Study: 393081

Group type: EXPERIMENTAL
Intervention: 5‐(3‐pyridyl) tetrazole
Number of subjects: 15
Study: 29880098

Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 589

Group type: COMPARATOR
Intervention: Mechanical compression
Number of subjects: 589
Study: 27653268

Group type: EXPERIMENTAL
Intervention: 7th Generation (Ormco) lingual brackets
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: STb (Ormco) lingual brackets
Number of subjects: 46
Study: 25312449

Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1271
Study: 24300203

Group type: EXPERIMENTAL
Intervention: Home enteral nutrition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hospital enteral nutrition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 82
Study: 20958119

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg b.i.d.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 μg b.i.d.
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study: 19999219

Group type: EXPERIMENTAL
Intervention: Continuous low pressure suction (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water seal only (Group II)
Number of subjects: 100
Study: 16864166

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Control (no postoperative RT)
Number of subjects: 1046
Study: 14657866

Group type: COMPARATOR
Intervention: Maternal serum progesterone levels (mean 81.0 nmol/L in asthmatic children)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Maternal serum estradiol levels (mean 7.87 nmol/L in asthmatic children)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Maternal serum free estradiol levels (mean 149.5 pmol/L in asthmatic children)
Number of subjects: 254
Study: 10714839

Group type: COMPARATOR
Intervention: Coracoid approach (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Axillary approach (A)
Number of subjects: 60
Study: 9179519

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine and Placebo
Number of subjects: 0
Study: 8210915

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin‐2 (rIL‐2) activated spleen-derived lymphokine‐activated killer (LAK) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of Adriamycin followed by LAK cells
Number of subjects: 0
Study: 3535544

Group type: EXPERIMENTAL
Intervention: Gradual tapering of alprazolam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31713265

Group type: EXPERIMENTAL
Intervention: THRIVE (text messaging intervention); 1-2 health-related text messages per day over 16 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: AYA survivor handbook; control group
Number of subjects: 61
Study: 29649022

Group type: EXPERIMENTAL
Intervention: Skills and Philosophy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Skills only
Number of subjects: 298

Group type: COMPARATOR
Intervention: Philosophy only
Number of subjects: 298

Group type: COMPARATOR
Intervention: Physical Fitness (Placebo)
Number of subjects: 298
Study: 27628038

Group type: EXPERIMENTAL
Intervention: Qing-Xin-Jie-Yu Granules (QXJYG), twice daily for 6 months
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo granules, twice daily for 6 months
Number of subjects: 1500
Study: 24309220

Group type: EXPERIMENTAL
Intervention: IUB (intrauterine ball)
Number of subjects: 15
Study: 22909147

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (various combinations)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: OLM/AML (dual therapy)
Number of subjects: 2690

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (40mg/5mg/25mg, 40mg/10mg/12.5mg, 40mg/10mg/25mg)
Number of subjects: 2690
Study: 19943833

Group type: EXPERIMENTAL
Intervention: Combination of medication and interpersonal psychotherapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Open treatment with antidepressant medication
Number of subjects: 244
Study: 19043609

Group type: EXPERIMENTAL
Intervention: Inhalation of fucose/galactose solution for 21 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined therapy (inhalation and intravenous antibiotics)
Number of subjects: 11
Study: 15994852

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naloxone (in women with HRT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14616169

Group type: EXPERIMENTAL
Intervention: Intravenous Group (omeprazole, clarithromycin, amoxicillin-clavulanic acid intravenously b.d. for 3 days followed by 7 days of oral omeprazole plus placebo)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral Group (intravenous omeprazole plus placebo followed by 7 days of oral omeprazole, clarithromycin and amoxicillin b.d.)
Number of subjects: 75
Study: 10805221

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant glycosylated interleukin 6 (rhIL-6) at 1-10 microg/kg/day
Number of subjects: 10
Study: 8897118

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study: 1325013

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (group HC) with reduced heparin dose of 225 IU/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncoated circuits (group C) with standard heparin dose of 300 IU/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (group HC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncoated circuits (group C)
Number of subjects: 14
Study: 6189328

Group type: EXPERIMENTAL
Intervention: 0.2 mg/1 trioxsalen bath PUVA therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: equipotent methoxsalen bath PUVA therapy
Number of subjects: 22
Study: 31801514

Group type: EXPERIMENTAL
Intervention: Nutritional intervention group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard dietary counseling (control group)
Number of subjects: 228
Study: 28689006

Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: No statin use
Number of subjects: 969
Study: 27502769

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 24399744

Group type: EXPERIMENTAL
Intervention: Benfotiamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiamine hydrochloride
Number of subjects: 0
Study: 23247442

Group type: EXPERIMENTAL
Intervention: Degradable chitin conduit tublization group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional epineurial neurorrhaphy group
Number of subjects: 30
Study: 20561619

Group type: EXPERIMENTAL
Intervention: Uncovered WallFlex stent
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Covered Comvi stent
Number of subjects: 151
Study: 17721089

Group type: EXPERIMENTAL
Intervention: HIV vaccine trials
Number of subjects: 0
Study: 16231758

Group type: EXPERIMENTAL
Intervention: Coffee intake of more than 3 cups per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-coffee drinking
Number of subjects: 42